[1] Miele L. Notch signaling[J]. Clin Cancer Res,2006,12(4):1074-1079.
[2] Miele L, Golde T, Osborne B. Notch signaling in cancer[J]. Curr Mol Med,2006,6(8):905-918.
[3] Logeat F, Bessia C, Brou C, et al. The Notch1 receptor is cleaved constitutively by a furin-like convertase[J]. Proc Natl Acad Sci U S A,1998,95(14):8108-8112.
[4] Kovall R A. Structures of CSL, Notch and Mastermind proteins: piecing together an active transcription complex[J]. Curr Opin Struct Biol,2007,17(1):117-127.
[5] Bunting K D. ABC transporters as phenotypic markers and functional regulators of stem cells[J]. Stem Cells,2002,20(1):11-20.
[6] Mimeault M, Hauke R, Mehta P P, et al. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers[J]. J Cell Mol Med,2007,11(5):981-1011.
[7] Weijzen S, Rizzo P, Braid M, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells[J]. Nat Med,2002,8(9):979-986.
[8] Harrison H, Farnie G, Howell S J, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor[J]. Cancer Res,2010,70(2):709-718.
[9] Zhang X P, Zheng G, Zou L, et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells[J]. Mol Cell Biochem,2008,307(1-2):101-108.
[10] Sriuranpong V, Borges M W, Ravi R K, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells[J]. Cancer Res,2001,61(7):3200-3205.
[11] Nakakura E K, Sriuranpong V R, Kunnimalaiyaan M, et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling[J]. J Clin Endocrinol Metab,2005,90(7):4350-4356.
[12] Haruki N, Kawaguchi K S, Eichenberger S, et al. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers[J]. Cancer Res,2005,65(9):3555-3561.
[13] Zagouras P, Stifani S, Blaumueller C M, et al. Alterations in Notch signaling in neoplastic lesions of the human cervix[J]. Proc Natl Acad Sci U S A,1995,92(14):6414-6418.
[14] Palomero T, Mckenna K, O-Neil J, et al. Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias[J]. Leukemia,2006,20(11):1963-1966.
[15] Callahan R, Smith G H. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways[J]. Oncogene,2000,19(8):992-1001.
[16] Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival[J]. Cancer Res,2005,65(18):8530-8537.
[17] Muller C S. Notch signaling and malignant melanoma[J]. Adv Exp Med Biol,2012,727:258-264.
[18] Gao J, Song Z, Chen Y, et al. Deregulated expression of Notch receptors in human hepatocellular carcinoma[J]. Dig Liver Dis,2008,40(2):114-121.
[19] Mullendore M E, Koorstra J B, Li Y M, et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer[J]. Clin Cancer Res,2009,15(7):2291-2301.
[20] Du X, Zhao Y P, Zhang T P, et al. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer[J]. World J Surg,2013,37(7):1688-1694.
[21] Zhu H, Zhou X, Redfield S, et al. Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers[J]. Am J Transl Res,2013,5(3):368-378.
[22] Yan M, Plowman G D. Delta-like 4/Notch signaling and its therapeutic implications[J]. Clin Cancer Res,2007,13(24):7243-7246.
[23] Noguera-Troise I, Daly C, Papadopoulos N J, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis[J]. Nature,2006,444(7122):1032-1037.
[24]Mehta K, Osipo C. Trastuzumab resistance: role for Notch signaling[J]. ScientificWorldJournal,2009,9:1438-1448.
[25] Moellering R E, Cornejo M, Davis T N, et al. Direct inhibition of the NOTCH transcription factor complex[J]. Nature,2009,462(7270):182-188. |